2-Brom-DL-tyrosin | 54788-42-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Brom-DL-tyrosin
• 英文别名: 2-Amino-3-(2-bromo-4-hydroxyphenyl)propanoic acid
• CAS: 54788-42-0
• 化学式: C₉H₁₀BrNO₃
• 分子量: 260.087
• InChiKey: UBPJIGYYLTZEDD-UHFFFAOYSA-N

物化性质

• 沸点：
  430.0±45.0 °C(Predicted)
• 密度：
  1.710±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  83.6
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2922509090

反应信息

• 作为产物：
  描述：

  2-溴-4-甲氧基溴苄 在 氢溴酸 作用下， 生成 2-Brom-DL-tyrosin
  参考文献：
  名称：

  Synthesis and microbiological activities of some monohalogenated analogs of tyrosine

  摘要：

  2-Chlorotyrosine and 2-bromotyrosine, as well as the previously reported 2-fluorotyrosine, were synthesized by hydrolysis of the condensation products from the appropriate benzyl bromide and ethyl acetamidomalonate and were compared with the corresponding 3-halotyrosines as growth inhibitors of Escherichia coli 9723, Streptococcus faecalis 8043 and Lactobacillus plantarum 8014. In contrast to the 2- and 3-fluorotyrosines which were equally effective as growth inhibitors, the 2-chloro- and 2-bromotyrosines were much more effective than the 3-chloro- and 3-bromotyrosines in inhibiting the growth of the three microorganisms. For each of the assay organisms, the growth inhibitions of all three 2-halotyrosines were reversed competitively in varying degrees by tyrosine.

  DOI：

  10.1021/jm00235a006

文献信息

• Diagnostic and therapeutic agents
  申请人：Taube Seija

  公开号：US20070258899A1

  公开（公告）日：2007-11-08

  Tumor targeting units are disclosed which have a peptide sequence C y —Y—G-F—X—W-G-Z-C yy (SEQ ID NO: 25), or a pharmaceutically or physiologically acceptable salt thereof. Tumor targeting agents are also disclosed having at least one targeting unit, directly or indirectly coupled to at least one effector unit. Diagnostic or pharmaceutical compositions having at least one targeting unit or at least one targeting agent, and targeting units or targeting agents for the preparation of a medicament for the treatment of cancer related diseases (including cancer), especially for the treatment of colon/colorectal cancer or its metastases are also disclosed.

  揭示了具有肽序列Cy—Y—G-F—X—W-G-Z-Cyy（序列ID编号：25）或其药学或生理上可接受的盐的肿瘤靶向单元。还披露了具有至少一个靶向单元的肿瘤靶向剂，直接或间接地偶联至至少一个效应单元。还披露了具有至少一个靶向单元或至少一个靶向剂的诊断或药物组合物，以及用于制备治疗癌症相关疾病（包括癌症）的药物的靶向单元或靶向剂，特别是用于治疗结肠/结直肠癌或其转移的靶向单元或靶向剂。
• Process for the preparation of mixtures of trifluoroacetyl glatiramer acetate using purified hydrobromic acid
  申请人：Teva Pharmaceutical Industries Ltd.

  公开号：EP2177528A1

  公开（公告）日：2010-04-21

  The Subject invention provides an improved process for obtaining a mixture of polypeptides having nonuniform amino acid sequences, where each polypeptide consists essentially of alanine, glutamic acid, tyrosine and lysine where the resulting mixture of polypeptides comprises less than 0.3% brominated tyrosine and less than 1000 ppm metal ion impurities.

  本发明提供了一种改进的工艺，用于获得具有不均匀氨基酸序列的多肽混合物，其中每个多肽基本上由丙氨酸、谷氨酸、酪氨酸和赖氨酸组成，所得到的多肽混合物中溴化酪氨酸含量低于 0.3%，金属离子杂质含量低于 1000 ppm。
• Process for preparation of mixtures of polypeptides using purified hydrobromic acid
  申请人：Dolitzky Ben-Zion

  公开号：US20060052586A1

  公开（公告）日：2006-03-09

  The subject invention provides an improved process for obtaining a mixture of polypeptides having nonuniform amino acid sequences, where each polypeptide consists essentially of alanine, glutamic acid, tyrosine and lysine where the resulting mixture of polypeptides comprises less than 0.3% brominated tyrosine and less than 1000 ppm metal ion impurities.

  本发明提供了一种改进的工艺，用于获得具有不均匀氨基酸序列的多肽混合物，其中每种多肽基本上由丙氨酸、谷氨酸、酪氨酸和赖氨酸组成，所得到的多肽混合物中溴化酪氨酸含量低于 0.3%，金属离子杂质含量低于 1000 ppm。
• PROCESS FOR PREPARATION OF MIXTURES OF POLYPEPTIDES USING PURIFIED HYDROBROMIC ACID
  申请人：Teva Pharmaceutical Industries Ltd

  公开号：EP1799703A2

  公开（公告）日：2007-06-27
• EP1799703A4
  申请人：——

  公开号：EP1799703A4

  公开（公告）日：2008-09-03